Merck Animal Health Announces 2016 Gustav Rosenberger Memorial Fund Scholarship Winner

MADISON, NEW JERSEY, July 3, 2016 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) is proud to support the award of the Gustav Rosenberger Memorial Fund Scholarship to Dr. Guilherme Rizzoto, a veterinarian from Brazil, at The World Buiatrics Congress in Dublin, Ireland, on July 3, 2016. The Gustav Rosenberger Memorial Fund (GRMF) works to further improve bovine medicine at an international level and to stimulate bovine research in its broadest sense.

Dr. Guilherme Rizzoto was selected by the GRMF board based on a combination of his educational background, experience, potential for further development and research plans related to the affect heat stress has on fertility in different bull breeds. Understanding temperature regulation will allow Rizzoto to research potential new options to prevent and treat infertility in bulls – a relevant topic in Brazil. His research will continue under the supervision of Professor John P. Kastelic, University of Calgary.

“Brazil is one of the largest exporters of beef in the world and we raise these cattle in one of the warmest climates,” said Rizzoto. “It is vital that we understand the implications heat stress has on bulls in order to identify best practices for improving reproduction and ultimately the economic success of this industry in our country.”

The Global Ruminants Business Unit at Merck Animal Health is proud to support and invest in young professionals and veterinarians at the start of their professional career who are vital to our future. The service, ideas, and insights they will provide throughout their careers will well exceed the scope of the education and support they receive.

Please visit for more information about the scholarship. To learn more about World Buiatric Congress go to

About Merck Animal Health
For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedInFacebook and Twitter.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA           
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (